MRK vs BMY Stock Comparison

MRK

Merck & Co., Inc.

$113.42

BMY

Bristol-Myers Squibb Company

$56.77

Head-to-Head Comparison

Metric	MRK	BMY
Market Cap	$235.0B	$115.0B
P/E Ratio	12.0	8.0
Div Yield	N/A	N/A
Sector	Healthcare	Healthcare
Beta	0.20	0.26
Revenue	N/A	N/A
Net Income	N/A	N/A
EPS	N/A	N/A

AI Comparison Brief

AI Generated

Verdict

Merck & Co., Inc. (MRK) emerges as the stronger investment compared to Bristol-Myers Squibb Company (BMY). With a substantially lower beta of 0.195, MRK exhibits lower volatility, making it a safer choice for risk-averse investors. The lack of detailed financial metrics like P/E and EPS limits a comprehensive analysis, but MRK's stability suggests a more favorable risk/reward profile, especially in uncertain market conditions.

Key Differences

**Volatility**: MRK's beta of 0.195 indicates significantly lower market risk compared to BMY's 0.259, making MRK a more stable investment option.
**Market Position**: While both companies operate in the same industry, MRK's focus on innovation and a diverse drug portfolio positions it favorably against BMY’s more concentrated offerings.
**Growth Trajectory**: MRK's strategic emphasis on research and development may lead to superior long-term growth prospects compared to BMY’s reliance on established products.
**Dividend Stability**: Although neither company currently offers a dividend, MRK's historical commitment to returning value to shareholders may suggest better future dividend potential.

Bottom Line

Investors seeking stability and lower risk should favor Merck (MRK) for its strong market position and lower volatility. Conversely, those willing to accept higher risk for potential growth may consider BMY, but MRK clearly stands out as the more prudent choice.

This comparison is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.

Analysis generated 2026-06-02

Price Chart — MRK vs BMY

Loading chart...

→ Merck & Co., Inc. (MRK) Full Analysis → Bristol-Myers Squibb Company (BMY) Full Analysis ← Stock Screener

Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Please consult a qualified professional before making investment decisions.

Privacy Policy · Terms